Summary
Background SARS-CoV-2 vaccination of persons aged 12 years and older has reduced disease burden in the United States. The COVID-19 Scenario Modeling Hub convened multiple modeling teams in September 2021 to project the impact of expanding vaccine administration to children 5-11 years old on anticipated COVID-19 burden and resilience against variant strains.
Methods Nine modeling teams contributed state- and national-level projections for weekly counts of cases, hospitalizations, and deaths in the United States for the period September 12, 2021 to March 12, 2022. Four scenarios covered all combinations of: 1) presence vs. absence of vaccination of children ages 5-11 years starting on November 1, 2021; and 2) continued dominance of the Delta variant vs. emergence of a hypothetical more transmissible variant on November 15, 2021. Individual team projections were combined using linear pooling. The effect of childhood vaccination on overall and age-specific outcomes was estimated by meta-analysis approaches.
Findings Absent a new variant, COVID-19 cases, hospitalizations, and deaths among all ages were projected to decrease nationally through mid-March 2022. Under a set of specific assumptions, models projected that vaccination of children 5-11 years old was associated with reductions in all-age cumulative cases (7.2%, mean incidence ratio [IR] 0.928, 95% confidence interval [CI] 0.880-0.977), hospitalizations (8.7%, mean IR 0.913, 95% CI 0.834-0.992), and deaths (9.2%, mean IR 0.908, 95% CI 0.797-1.020) compared with scenarios where children were not vaccinated. This projected effect of vaccinating children 5-11 years old increased in the presence of a more transmissible variant, assuming no change in vaccine effectiveness by variant. Larger relative reductions in cumulative cases, hospitalizations, and deaths were observed for children than for the entire U.S. population. Substantial state-level variation was projected in epidemic trajectories, vaccine benefits, and variant impacts.
Conclusions Results from this multi-model aggregation study suggest that, under a specific set of scenario assumptions, expanding vaccination to children 5-11 years old would provide measurable direct benefits to this age group and indirect benefits to the all-age U.S. population, including resilience to more transmissible variants.
Competing Interest Statement
JL has served as an expert witness on cases where the likely length of the pandemic was of issue. MCR reports stock ownership in Becton Dickinson & Co., which manufactures medical equipment used in COVID-19 testing, vaccination, and treatment. JS and Columbia University disclose partial ownership of SK Analytics. JS discloses consulting for BNI. There are no other competing interests to declare.
Funding Statement
K. Shea acknowledges support from two National Science Foundation (NSF) COVID-19 RAPID awards 2028301 and 2126278. R. K. Borchering was funded by NSF COVID-19 RAPID award 2028301. E. A. Howerton and K. Shea acknowledge support from the Huck Institutes for the Life Sciences at The Pennsylvania State University. N. G. Reich was supported by the US CDC (1U01IP001122) and by the National Institutes of General Medical Sciences (NIGMS) (R35GM119582). L. Contamin, J. Levander, and J. Kerr, J. Espino, and H. Hochheiser were supported by NIGMS 5U24GM132013-02. M. Kinsey, K. Tallaksen, S. Wilson, L. Shin, L. Mullany, K. Rainwater-Lovett were supported by the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR) HHS/ASPR Contract # 75A50121C00003. M. Chinazzi, K. Mu, and A. Vespignani were supported by HHS/CDC 5U01IP0001137. J. Davis, A. Pastore y Piontti, and A. Vespignani were supported by HHS/CDC 6U01IP001137. A. Srivastava was supported by NSF Grant No. 2027007. S. A. Truelove, E. C. Lee, J. Lemaitre, C. Smith, J. Kaminsky, and J. Lessler acknowledge support from the Johns Hopkins Health System, the US Department of Health and Human Services / US Department of Homeland Security (DHHS/DHS), the State of California, the Johns Hopkins University Modeling and Policy Hub, and the Office of the Dean at the Johns Hopkins Bloomberg School of Public Health. S. A. Truelove, E. C. Lee, J. Kaminsky, J. Dent, and C. Smith acknowledge support from NSF, Grant No. 2127976. J. Lessler acknowledges support the National Institutes of Health (NIH) Grant R01GM140564. J. Lemaitre acknowledges support from the Swiss National Science Foundation. J. Dent was supported by the State of California. P. Porebski , S. Venkatramanan, A. Adiga, B. Lewis, B. Klahn, J. Outten, B. Hurt, H. Mortveit, A. Wilson, M. Marathe, J. Chen, S. Hoops, P. Bhattacharya, D. Machi acknowledge support from CDC grants 75D30119C05935 and U01CK000589, NSF grants CCF-1918656 and IIS-1931628, NIH grant 2R01GM109718-0, Dept of Defense - DTRA grant HDTRA1-19-D-0007, Virginia Dept Health awards VDH-21-501-0135 and VDH-21-501-0135, Virginia Dept of Emergency Management, UVA (internal seed grants). This research is based on survey results from Carnegie Mellon University Delphi Group. G. España and A. Perkins received funding from an NSF RAPID grant (DEB 2027718). S. Chen received funding from the Models of Infectious Disease Agent Study (MIDAS) Network (MIDASUP-05) and the North Carolina Biotechnology Center (2020FLG3898). J. Shaman, S. Pei, T. Yamana and M. Galanti were supported by NIH Grant R01AI163023, CSTE Grant NU38OT000297 and a gift from the Morris-Singer Foundation. JS and Columbia University disclose partial ownership of SK Analytics. JS discloses consulting for BNI.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This analysis was conducted using publicly available, aggregated data on cases, hospitalizations, and deaths, along with published parameter estimates. No human subjects research was involved, and no IRB approval was required.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* co-first authors
Data Availability
All projection results are publicly available. Other data referred to in the manuscript are from publicly available sources cited in the manuscript.
https://covid19scenariomodelinghub.org/
https://github.com/midas-network/covid19-scenario-modeling-hub
